Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer.

Heliyon · 2024 · PMC10944256 · PMID 38496877

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendP = 0.056so close (0.05 < p ≤ 0.1)

Gefitinib showed a trend of longer mPFS in L858R cohort than in 19Del cohort (27.5 months vs. 10.3 months, P = 0.056).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.